PT - JOURNAL ARTICLE AU - Azeez, Rilwan AU - Lotoski, Larisa AU - Dubeau, Aimée AU - Rodriguez, Natalie AU - Reyna, Myrtha E. AU - Freitas, Tyler AU - Goguen, Stephanie AU - Medeleanu, Maria AU - Winsor, Geoffrey L. AU - Brinkman, Fiona S.L. AU - Cameron, Emily E. AU - Roos, Leslie AU - Simons, Elinor AU - Moraes, Theo J. AU - Mandhane, Piush J. AU - Turvey, Stuart E. AU - Bolotin, Shelly AU - Wright, Kim AU - McNeil, Deborah AU - Patrick, David M. AU - Bullard, Jared AU - Langlois, Marc-André AU - Arnold, Corey R. AU - Galipeau, Yannick AU - Pelchat, Martin AU - Doucas, Natasha AU - Subbarao, Padmaja AU - Azad, Meghan B. TI - Investigating SARS-CoV-2 infection and the health and psychosocial impact of the COVID-19 pandemic in the Canadian CHILD Cohort: study methodology and cohort profile AID - 10.1101/2022.10.19.22281242 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.19.22281242 4099 - http://medrxiv.org/content/early/2022/10/21/2022.10.19.22281242.short 4100 - http://medrxiv.org/content/early/2022/10/21/2022.10.19.22281242.full AB - Background The COVID-19 pandemic is affecting all Canadian families, with some impacted differently than others. Our study aims to: 1) determine the prevalence and transmission of SARS-CoV-2 infection among Canadian families, 2) identify predictors of infection susceptibility and severity of SARS-CoV-2 and 3) identify health and psychosocial impacts of the COVID-19 pandemic.Methods This study builds upon the CHILD Cohort Study, an ongoing multi-ethnic general population prospective cohort consisting of 3454 Canadian families with children born in Vancouver, Edmonton, Manitoba, and Toronto between 2009-12. During the pandemic, 1462 CHILD households (5378 individuals) consented to participate in the CHILD COVID-19 Add-On Study involving: (1) brief biweekly surveys about COVID-19 symptoms and testing; (2) quarterly questionnaires assessing COVID-19 exposure, testing and vaccination status, physical and mental health, and pandemic-driven life changes; (3) in-home biological sampling kits to collect blood and stool. Mean ages were 9 years (range 0-17) for children and 43 years (range 18-85) for adults. Prevalence of SARS-CoV-2 infection will be estimated from survey data and confirmed through serology testing. We will combine these new data with a wealth of pre-pandemic CHILD data and use multivariate modelling and machine learning methods to identify risk and resilience factors for susceptibility and severity to the direct and indirect effects of the pandemic.Interpretation Our short-term findings will inform key stakeholders and knowledge users to shape current and future pandemic responses. Additionally, this study provides a unique resource to study the long-term impacts of the pandemic as the CHILD Cohort Study continues.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the Canadian Institutes of Health Research and the Canadian COVID-19 Immunity Task Force [VR5-172658] and Research Manitoba [4494].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the University of British Columbia (H20-02324), University of Alberta (Pro00102524), University of Manitoba (HS24250), The Hospital for Sick Children (1000071220) and McMaster University (1108).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://childstudy.ca/for-researchers/study-data/. ACE2Angiotensin-converting Enzyme 2BCBritish ColumbiaCANCOGENCanadian COVID Genomics NetworkCANUECanadian Urban Environmental Health Research ConsortiumCHILDCanadian Healthy Infant Longitudinal DevelopmentCINECACommon Infrastructure for National Cohorts in Europe, Canada, and AfricaCOVID-19Coronavirus disease 2019CRISISCoRonavIruS Health Impact SurveyDBSDried Blood SpotsELISAEnzyme-linked Immunosorbent AssayIgGImmunoglobulin GNCCNational Coordinating CentreNGOsNon-Governmental OrganizationsREDCapResearch Electronic Data CaptureSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SNPSingle Nucleotide PolymorphismsUNESCOUnited Nations Educational, Scientific and Cultural OrganizationUNICEFUnited Nations Children’ s FundWHOWorld Health Organization